Apr 28, 2012 - 10:28 pm
This applies specifically to Peripheral T-Cell Lymphomas. At treatment Monday, I was advised by my clinical trial/study nurse that a couple of new combinations are being worked on by Fred Hutchinson:
Specifically, I-CEOP, which will combine Istodax (Romidepsin) with Etoposide, vincristine, prednisone, and cycolophosphamide, while eliminating doxorubicin and its well-known toxicities. It has the potential to be an alternative to EPOCH for some patients.
Secondly, Istodax combined with Folotyn (Pralatrexate).
Of course, trials will determine their ultimate efficacy. As I am here to attest, Istodax has been amazingly successful in defeating and apparently suppressing Peripheral T-Cell Lymphoma (NOS) for three years now. If successful when used in combination with both standard and newly introduced chemo agents, I think that hope continues to increase for our tiny (but growing) bunch of T-cellers.
The potential here is for the development and introduction of a standard therapy for PTCL, where none exists now. This would be great news. Must here add that my scans are still NED. Thank you, Lord!